HP 537
Alternative Names: HP-537Latest Information Update: 28 Feb 2025
At a glance
- Originator Hinova pharmaceuticals
- Class Antineoplastics
- Mechanism of Action P300-CBP transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Breast cancer; Haematological malignancies; Multiple myeloma
- No development reported Cancer; Prostate cancer
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Cancer in China
- 28 Feb 2025 No recent reports of development identified for preclinical development in Prostate-cancer in China
- 05 Apr 2024 Pharmacodynamics data from the preclinical studies in Haematological malignancies presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)